New Zealand’s drug-funding agency, Pharmac, has moved the weight-loss medication Wegovy onto its list of medicines suitable for future funding, marking a significant step toward public subsidies for the popular GLP-1 agonist. While the move does not mean the drug is immediately free or subsidized for all, it places semaglutide—the active ingredient in Wegovy—on the “Options for Investment” list, a category of medications Pharmac would fund if budget constraints allow.
The decision, released Thursday, follows a high-priority recommendation from Pharmac’s obesity treatments advisory group in February. For many New Zealanders currently paying roughly $400 per month out-of-pocket for the treatment, the move represents a potential shift in how chronic weight management is handled within the public health system.
However, the path to access remains narrow. If the drug is officially funded, it will not be available to everyone struggling with weight. Instead, eligibility will be restricted to those with a Body Mass Index (BMI) of 35 or higher who also present with at least two specific weight-related comorbidities.
Strict Eligibility and the BMI Threshold
The criteria for potential funding reflect a tension between public health needs and the massive fiscal impact of providing expensive weight-loss drugs to a large portion of the population. The original application sought funding for adults with a BMI over 30. However, data from the 2024/25 New Zealand Health Survey suggests that such a threshold would encompass approximately 34 percent of New Zealanders over the age of 15.
To ensure the treatment reaches those with the highest clinical need, the advisory committee raised the threshold to a BMI of 35. This alignment mirrors the approach taken in other comparable healthcare systems, including those in England, Scotland, and Canada.
Under the proposed guidelines, patients would qualify for funded treatment based on the following tiers:
- BMI of 50 or more: Eligible for funding regardless of other health conditions.
- BMI of 35 to 49: Eligible only if they have at least two of the following comorbidities: hypertension, diabetes, dyslipidaemia, obstructive sleep apnoea, or established cardiovascular disease.
The committee also noted a further contingency: if the cost of treating those at the BMI 35 level proves to be cost-prohibitive or lacks sufficient cost-effectiveness, the threshold could be raised again to a BMI of 40.
The ‘Options for Investment’ Waiting Room
It is important for patients to understand that the “Options for Investment” list is not a guarantee of immediate funding. It essentially serves as a prioritized waiting list. Pharmac does not disclose the specific order of this list for commercial reasons, meaning there is no public timeline for when Wegovy will move from “suitable for future funding” to “currently funded.”
The agency acknowledged that the budget impact of funding semaglutide for weight management would be “very high,” given the prevalence of obesity and related comorbidities across the country. This financial pressure is a primary reason why the agency is implementing strict clinical hurdles and performance markers.
One such marker is a mandatory efficacy check. The recommendation includes a condition that treatment must be discontinued if a patient does not achieve at least a 10 percent reduction in body weight after six months of use. This ensures that limited public resources are directed toward patients who respond clinically to the medication.
Clinical Context: Beyond the Scale
As a physician, it is important to frame this discussion not as a matter of aesthetics, but as a matter of metabolic health. Wegovy belongs to a class of drugs known as GLP-1 receptor agonists, which mimic a hormone that targets areas of the brain that regulate appetite and food intake. By slowing gastric emptying and increasing feelings of fullness, these medications can lead to significant weight loss.
The comorbidities listed by Pharmac—such as obstructive sleep apnoea and hypertension—are not incidental; they are often the primary drivers of long-term disability and mortality in patients with obesity. Reducing weight by 10 percent or more can lead to a measurable decrease in the severity of these conditions, potentially reducing the long-term burden on the hospital system.
| Patient Category | BMI Requirement | Additional Requirements |
|---|---|---|
| High-Need | 50+ | None |
| Clinical Need | 35–49 | Two or more comorbidities |
| Potential Limit | 40+ | Proposed if costs are prohibitive |
The comorbidities specifically identified for eligibility include:
- Hypertension: High blood pressure.
- Diabetes: Specifically Type 2 diabetes.
- Dyslipidaemia: Abnormal levels of lipids (cholesterol/triglycerides) in the blood.
- Obstructive Sleep Apnoea: A disorder where breathing repeatedly stops and starts during sleep.
- Cardiovascular Disease: Established heart-related conditions.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult with a licensed healthcare provider regarding weight management and medication eligibility.
The next phase for Wegovy involves Pharmac’s internal budgetary reviews to determine when the drug can move from the investment list to active funding. Patients currently paying for the drug privately should continue to follow their prescribing physician’s guidance while awaiting official updates from Pharmac.
Do you think the BMI 35 threshold is a fair limit for public funding? Share your thoughts in the comments or share this story with someone who may be affected.
